Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JAGX NASDAQ:MLND NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Animal Health$1.29+2.5%$2.75$1.02▼$92.75$782K-0.1196,013 shs32,310 shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shsTNXPTonix Pharmaceuticals$10.92-5.5%$12.37$10.03▼$69.97$174.62M1.64456,762 shs159,241 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Animal Health-0.40%-41.94%-44.00%-91.22%-98.51%MLNDMillendo Therapeutics0.00%0.00%0.00%0.00%-75.22%TNXPTonix Pharmaceuticals+5.28%+4.52%-3.75%-11.82%-74.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Animal Health$1.29+2.5%$2.75$1.02▼$92.75$782K-0.1196,013 shs32,310 shsMLNDMillendo Therapeutics$1.56$4.00$0.92▼$16.95$29.71M0.481.52 million shs152,321 shsTNXPTonix Pharmaceuticals$10.92-5.5%$12.37$10.03▼$69.97$174.62M1.64456,762 shs159,241 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Animal Health-0.40%-41.94%-44.00%-91.22%-98.51%MLNDMillendo Therapeutics0.00%0.00%0.00%0.00%-75.22%TNXPTonix Pharmaceuticals+5.28%+4.52%-3.75%-11.82%-74.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar Animal Health 1.00SellN/AN/AMLNDMillendo Therapeutics 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$24.00119.78% UpsideCurrent Analyst Ratings BreakdownLatest JAGX, MLND, and TNXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026JAGXJaguar Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$26.006/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/5/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Animal Health$11.51M0.07N/AN/A($106.11) per share-0.01MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ATNXPTonix Pharmaceuticals$13.11M13.28N/AN/A$19.17 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Animal Health-$53.43M-$591.92N/AN/AN/A-169.04%N/A-115.55%8/13/2026 (Estimated)MLNDMillendo Therapeutics-$36.41MN/AN/AN/AN/AN/A-91.03%-72.44%N/ATNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest JAGX, MLND, and TNXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026JAGXJaguar Animal Health-$52.15N/AN/AN/A$4.24 millionN/A8/10/2026Q2 2026TNXPTonix Pharmaceuticals-$2.64N/AN/AN/A$7.72 millionN/A5/20/2026Q1 2026JAGXJaguar Animal Health-$149.10-$13.60+$135.50-$13.60$4.21 million$20.27 million5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar Animal HealthN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Animal HealthN/A0.500.30MLNDMillendo TherapeuticsN/A6.396.39TNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Animal Health12.04%MLNDMillendo TherapeuticsN/ATNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipJAGXJaguar Animal Health2.00%MLNDMillendo TherapeuticsN/ATNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Animal Health50600,000591,000No DataMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableTNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableJAGX, MLND, and TNXP HeadlinesRecent News About These CompaniesTonix Pharma announces upcoming retirement of chief medical officerJuly 21 at 4:51 PM | tipranks.comTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal ModelsJuly 15, 2026 | finance.yahoo.comTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal ModelsJuly 15, 2026 | globenewswire.comTonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)July 13, 2026 | investorshub.advfn.comTonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®July 13, 2026 | finance.yahoo.comTonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered LivesJuly 13, 2026 | quiverquant.comQTonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®July 13, 2026 | globenewswire.comTonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & HistoryJuly 10, 2026 | benzinga.comTonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History - Yahoo FinanceJuly 2, 2026 | finance.yahoo.comTonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold RatingJune 29, 2026 | seekingalpha.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | finance.yahoo.comTonix Pharma Begins Pivotal Phase 2 Depression TrialJune 29, 2026 | tipranks.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | globenewswire.comThis Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 25, 2026 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Purchases 1,415 SharesJune 16, 2026 | insidertrades.comWe're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn RateJune 13, 2026 | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11, 2026 | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11, 2026 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Newcomb Stillwell Purchases 5,000 SharesJune 10, 2026 | insidertrades.comWhy Is TNXP Stock Rising Today?June 8, 2026 | stocktwits.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAGX, MLND, and TNXP Company DescriptionsJaguar Animal Health NASDAQ:JAGX$1.29 +0.03 (+2.46%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Tonix Pharmaceuticals NASDAQ:TNXP$10.92 -0.64 (-5.54%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Texas Power Play: Hut 8 Sparks a $9.8B AI Infrastructure Deal Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
